Charles River Biotech Symposium| Biotechnology-Derived Therapeutics Perspectives on Nonclinical Development

Biopharmaceutical Development “Stories”

Biopharmaceutical company scientists present their current data on monoclonal antibodies, growth factors, vaccines, stem cell therapies, immunomodulatory agents and other biological entities. Issues that arise during nonclinical development, including safety concerns and regulatory hurdles, are also presented and discussed. 

 

Case Studies

The program will include our popular interactive case studies discussion.

 

Sessions & Hot Topics
Species Selection: The Foundation of Your Toxicology Program
Antibody Conjugates
Early Immunogenicity De-Risking in Industry
Gene Therapies & Gene Editing

PLANNING COMMITTEE

Jorg Blumel – Genentech

Frank Brennan – UCB Celltech
David Clarke - Eli Lilly
Mary Ellen Cosenza - MEC Regulatory Consulting

Ursula Jeffry - NGM Biopharmaceuticals

Doug Kornbrust – Preclinsight

Michael Leach - Pfizer

Dennis Meyer - Consultant

Jacintha Shenton - Janssen
Nicola Stagg - Genentech
Marque Todd - Pfizer

Lauren Black - Charles River

Joe Francisco - Charles River
Stephanie Gritz - Charles River
Marie-Soleil Piche - Charles River 

Outlook Outlook
iCal iCal
Google Google
Yahoo! Yahoo!
MSN MSN
Top